KryZ
2021-06-30
Biotechs are risky plays but can hit jackpot if lucky!
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":153580751,"tweetId":"153580751","gmtCreate":1625034591673,"gmtModify":1631887569725,"author":{"id":3574671514316116,"idStr":"3574671514316116","authorId":3574671514316116,"authorIdStr":"3574671514316116","name":"KryZ","avatar":"https://static.tigerbbs.com/91c62b44c75f8a4a9e0b7566bd02134d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":38,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Biotechs are risky plays but can hit jackpot if lucky!</p></body></html>","htmlText":"<html><head></head><body><p>Biotechs are risky plays but can hit jackpot if lucky!</p></body></html>","text":"Biotechs are risky plays but can hit jackpot if lucky!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/153580751","repostId":1100317118,"repostType":4,"repost":{"id":"1100317118","kind":"news","pubTimestamp":1625030487,"share":"https://www.laohunote.com/m/news/1100317118?lang=zh_CN&edition=full","pubTime":"2021-06-30 13:21","market":"us","language":"en","title":"These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317118","media":"Motley Fool","summary":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The ind","content":"<p>The <b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in <b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday<blockquote>这两家纳斯达克生物技术公司周二做出了令人瞠目结舌的举动</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-06-30 13:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The <b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.</p><p><blockquote>这个<b>纳斯达克复合材料</b>（纳斯达克指数：^IXIC）最近表现良好，创下新的历史新高。该指数周二保持势头，截至美国东部时间中午 12:30，上涨略高于 0.1%。</blockquote></p><p> The Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.<b>Cerevel Therapeutics Holdings</b>(NASDAQ:CERE)got a nice push higher, but investors in <b>Sensei Biotherapeutics</b>(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.</p><p><blockquote>纳斯达克以创新公司而闻名，周二，几只生物科技股受到了很多关注。<b>Cerevel Therapeutics控股</b>（纳斯达克股票代码：CERE）大幅上涨，但投资者<b>老师生物治疗</b>（纳斯达克股票代码：SNSE）没有那么幸运。下面，你会得到两种生物技术的详细信息。</blockquote></p><p> Cerevel serves up an early win</p><p><blockquote>Cerevel 早早获胜</blockquote></p><p> Shares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.</p><p><blockquote>Cerevel 股价周二中午上涨 95%，此前盘中早些时候上涨了一倍多。这家生物技术公司从其关键候选疗法之一传来了好消息。</blockquote></p><p> Cerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.</p><p><blockquote>Cerevel宣布其精神分裂症治疗CVL-231的早期临床试验取得积极结果。与接受安慰剂的患者相比，Cerevel治疗在患有该疾病的患者的常见评分系统中产生了统计学上的显著改善。CVL-231还产生了令人鼓舞的安全性和耐受性数据，这些数据在治疗的后期试验中应该是有价值的。</blockquote></p><p> The company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.</p><p><blockquote>该公司对结果感到满意。Cerevel 的首席科学官认为这些结果支持了更广泛的观点，即针对某些毒蕈碱受体的靶向治疗可以作为精神分裂症的可行治疗方法。与此同时，这位高管看到了避免其他类型治疗该疾病的主要副作用的潜力。</blockquote></p><p> Cerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.</p><p><blockquote>Cerevel 不到一年前通过与 Arya Sciences Acquisition 的 SPAC 合并上市。自那时以来，Cerevel 的股价远远高于其交易价格，现在已成为整个市场生物技术投资者的关注焦点。</blockquote></p><p> A disappointment for Sensei</p><p><blockquote>老师的失望</blockquote></p><p> Shares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.</p><p><blockquote>Sensei Biotherapeutics 的股价则相反，下跌超过 15%。投资者对这家免疫疗法专家对其治疗管线的战略重新优先顺序感到不满。</blockquote></p><p> Sensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.</p><p><blockquote>Sensei 决定将重点转移到目前的候选产品上，其中包括免疫噬菌体治疗 SNS-401-NG 和单克隆抗体 SNS-VISTA。通过这样做，它希望扩大可用现金来支付 2024 年上半年的成本。</blockquote></p><p> Unfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.</p><p><blockquote>不幸的是，这意味着Sensei将不再继续其SNS-301计划。在分析了单一抗原治疗的临床活动和特异性数据后，Sensei 相信它已经从第一代候选药物中获得了尽可能多的见解。Sensei应该很快就会采取进一步行动，SNS-VISTA研究将于今年年底进行，SNS-401-NG将在2022年下半年获得进一步关注。</blockquote></p><p> Sensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.</p><p><blockquote>Sensei 于 2 月初通过 IPO 上市，引起了相当大的兴趣。投资者对个性化癌症药物以更有效地治疗疾病的希望感到兴奋，Sensei 以每股 19 美元的价格向 IPO 投资者出售了 700 万股股票。首日的兴奋使该股高达每股 26.50 美元，但事实证明这些涨幅是短暂的，此后该股一直稳步走低。它现在的价格还不到IPO价格的一半。</blockquote></p><p> The biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.</p><p><blockquote>生物技术行业充满了赢家和输家，这是一个高风险领域，当事情进展顺利时可能会产生巨大的收益，当事情进展不顺利时可能会产生巨大损失。今天的消息传出后，Sensei 的未来似乎比之前更加值得怀疑，但投资者正在仔细研究 Cerevel 从长远来看可能会提供什么。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc."},"source_url":"https://www.fool.com/investing/2021/06/29/these-2-nasdaq-biotechs-made-eye-popping-moves-tue/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317118","content_text":"The Nasdaq Composite(NASDAQINDEX:^IXIC)has done well recently, pushing to new record levels. The index kept up its momentum on Tuesday, rising just over 0.1% as of 12:30 p.m. EDT.\nThe Nasdaq is known for innovative companies, and a couple ofbiotech stocksgot a lot of attention on Tuesday.Cerevel Therapeutics Holdings(NASDAQ:CERE)got a nice push higher, but investors in Sensei Biotherapeutics(NASDAQ:SNSE)weren't as fortunate. Below, you'll get the details on both biotechs.\nCerevel serves up an early win\nShares of Cerevel were up 95% at middayon Tuesday after having more than doubled earlier in the session. The biotech company had good news from one of its key candidate treatments.\nCerevel announced positive results in its early-stage clinical trial of schizophrenia treatment CVL-231. The Cerevel treatment produced statistically significant improvements in a common scoring system for patients suffering from the disease compared to those who received a placebo. CVL-231 also produced encouraging safety and tolerability data that should be valuable in later-stage trials of the treatment.\nThe company was pleased with the results. Cerevel's chief scientific officer sees the results as supporting the broader idea that targeted therapy for certain muscarinic receptors could work as a viable treatment for schizophrenia. At the same time, the executive sees the potential to avoid major side effects of other types of treatments for the disease.\nCerevel came public less than a year ago through a SPAC merger with Arya Sciences Acquisition. With the stock far above anywhere it has traded since then, Cerevel is now firmly on the radar for biotech investors across the market.\nA disappointment for Sensei\nShares of Sensei Biotherapeutics moved the other way, falling more than 15%. Investors weren't pleased to learn of the immunotherapy specialist's strategic reprioritization of its treatment pipeline.\nSensei made the decision to shift its priority to its current product candidates, which include the ImmunoPhage treatment SNS-401-NG and the monoclonal antibody SNS-VISTA. By doing so, it hopes to stretch its available cash to cover costs through the first half of 2024.\nUnfortunately, what that means is that Sensei will no longer continue its SNS-301 program. After analyzing clinical activity and data specific to the single-antigen treatment, Sensei believes that it has drawn as much insight as it can from its first-generation candidate. Further action from Sensei should come shortly, with SNS-VISTA studies coming by the end of this year and SNS-401-NG getting further attention in the second half of 2022.\nSensei just came public in early February through an IPO that generated considerable interest. Investors were excited by the hope of personalizing cancer medications to treat disease more effectively, and Sensei sold 7 million shares at $19 per share to IPO investors. First-day excitement sent the stock as high as $26.50 per share, but those gains proved short-lived, and the stock has moved steadily lower ever since. It now stands at less than half its IPO price.\nThe biotech industry is full of winners and losers, and it's a high-risk area that can produce huge gains when things go well and massive losses when they don't. Sensei's future seems more in doubt after today's news than it was before, but investors are taking a closer look at what Cerevel might have to offer over the long run.","news_type":1,"symbols_score_info":{"SNSE":0.9,"CERE":0.9}},"isVote":1,"tweetType":1,"viewCount":859,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":45,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/153580751"}
精彩评论